Elacestrant
Neoplasms
Stemline Therapeutics, Inc.Small moleculePhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 65/ 100
Competitive context
118 Active assets in the Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Hellenic Society of Hematology | Phase 3 | BB |
Feladilimab GlaxoSmithKline | Phase 2 | BB |
Carboplatin Bristol-Myers Squibb | Phase 3 | BB |
Cetuximab Mirati Therapeutics Inc. | Phase 4 | B |
PREDNISONE TABLETS The First Affiliated Hospital of Soochow University | Phase 3 | B |
View all 50 →
Same molecule, other indications
Elacestrant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →